The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Open accessAbstract
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study. METHODS: We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (> or =10 mg per week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate. Responses defined according to the criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses). RESULTS: At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent). In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P< or =0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P< or =0.004). All ACR responses were maintained at week 48 in the rituximab-methotrexate group. The majority of adverse events occurred with the first rituximab infusion: at 24 weeks, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups. Peripheral-blood immunoglobulin concentrations remained within normal ranges. CONCLUSIONS: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20 antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune disease”
From The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer (2015) · cites this paper as Edwards et al., 2004
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,248
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B. J., Fürst, D. E., Goldsmith, C. H., Kieszak, S. M., Lightfoot, R. W., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,639
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A. B., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J., & Cambridge, G. (2001) · Lara D. Veeken · doi:10.1093/rheumatology/40.2.205 · Cited by 525
Self-citationClinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 344
Self-citationvan Gestel, A. M., Anderson, J. J., van Riel, P. L. C. M., Boers, M., HAAGSMA, C. J., Rich, B., Wells, G. A., Lange, M., & Felson, D. T. (1999) · PubMed · Cited by 250
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
Edwards, E., Cambridge, & Abrahams (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00772.x · Cited by 174
The role of B cells in rheumatoid arthritis
Dörner, T., & Burmester, G. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00011 · Cited by 164
Flagged first, then by citations
Research works printed but not linked: 3
- Van Gestel AM, 1999, J Rheumatol, 26, 705
- Tighe H, Carson DA. Rheumatoid factors. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 5th ed. Vol. 1. Philadelphia: W.B. Saunders, 1997:241-9.
- McLaughlin P, 1999, Semin Oncol, 26, 79
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Rituximab reduces the incidence of acute graft-versus-host disease
Christopeit, M., Schütte, V., Theurich, S., Weber, T. E., Grothe, W., & Behre, G. (2009) · Blood · doi:10.1182/blood-2009-01-200527 · Cited by 41
Bobbio‐Pallavicini, F., Caporali, R. F., Alpini, C., Moratti, R., & Montecucco, C. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1398.034 · Cited by 42
Bokarewa, M. I., Lindholm, C., Zendjanchi, K., Nadali, M., & Tarkowski, A. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2007.01995.x · Cited by 42
Chen, D. R., & Cohen, P. L. (2012) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.12.7 · Cited by 42
Goto, S., Goto, H., Tanoshima, R., Kato, H., Takahashi, H., Sekiguchi, O., & Kai, S. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0269-6 · Cited by 42
Cells of the synovium in rheumatoid arthritis. B cells.
Mauri, C., & Ehrenstein, M. R. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2125 · Cited by 42
Intravenous rituximab for the treatment of cancer-associated retinopathy
Or, C., Collins, D. R., Merkur, A. B., Wang, Y., Chan, C., & Forooghian, F. (2013) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2012.11.010 · Cited by 42
Laragione, T., Brenner, M., Lahiri, A., Gao, E., Harris, C. L., & Gulko, P. S. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213498 · Cited by 42
Optimized nanoparticle-mediated delivery of CRISPR-Cas9 system for B cell intervention
Li, M., Fan, Y.-N., Chen, Z., Luo, Y., Wang, Y., Lian, Z., Xu, C., & Wang, J. (2018) · Nano Research · doi:10.1007/s12274-018-2150-5 · Cited by 43
Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids
Tannemaat, M. R., & Verschuuren, J. J. G. M. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.12.003 · Cited by 45
Geetha, D., Seo, P., Specks, U., & Fervenza, F. C. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01985.x · Cited by 42
Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis
Bracewell, C., Isaacs, J. D., Emery, P., & Ng, W. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903033919 · Cited by 42
Self-citationMuhammad, K., Roll, P., Einsele, H., Dörner, T., & Tony, H. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24722 · Cited by 42
Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis
Dass, S., Vital, E. M. J., & Emery, P. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.18.2559 · Cited by 42
Self-citationEffects of rituximab in two patients with dysferlin-deficient muscular dystrophy
Lerario, A., Cogiamanian, F. M., Marchesi, C., Belicchi, M., Bresolin, N., Porretti, L., & Torrente, Y. (2010) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-11-157 · Cited by 42
Signalling Pathways in B Cells: Implications for Autoimmunity
Dörner, T., & Lipsky, P. E. (2006) · Springer eBooks · doi:10.1007/3-540-29714-6_11 · Cited by 42
The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome
Meijer, J. M., Pijpe, J., Bootsma, H., Vissink, A., & Kallenberg, C. G. M. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8005-6 · Cited by 42
Dunussi‐Joannopoulos, K., Hancock, G. E., Kunz, A., Hegen, M., Zhou, X. X., Sheppard, B. J., Lamothe, J., Li, E., Ma, H., Hamann, P. R., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4547 · Cited by 42
The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes
Bloem, S. J., & Roep, B. O. (2017) · Diabetologia · doi:10.1007/s00125-017-4284-5 · Cited by 42
Adrenal Steroidogenesis after B Lymphocyte Depletion Therapy in New-Onset Addison's Disease
Pearce, S. H. S., Mitchell, A. L., Bennett, S., King, P., Chandran, S., Nag, S., Chen, S., Smith, B. R., Isaacs, J. D., & Vaidya, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1680 · Cited by 41
Outline of Salivary Gland Pathogenesis of Sjögren’s Syndrome and Current Therapeutic Approaches
Yura, Y., & Hamada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311179 · Cited by 47
Rituximab for Noninfectious Uveitis
Miserocchi, E., & Modorati, G. M. (2012) · Developments in ophthalmology · doi:10.1159/000336188 · Cited by 41
Rapid infusion of rituximab over 60 min
Tuthill, M. H., Crook, T., Corbet, T., King, J., & Webb, A. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01215.x · Cited by 41
Turkstra, E., Ng, S., & Scuffham, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.608655 · Cited by 48
Immunotherapy for Graves’ ophthalmopathy
Salvi, M. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000097 · Cited by 41
Emu, B., Luca, D., Offutt, C., Grogan, J. L., Rojkovich, B., Williams, M. B., Tang, M. T., Xiao, J. J., Lee, J. H., & Davis, J. C. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3554 · Cited by 41
Neuromyelitis Optica Spectrum Disorders
Sand, I. K. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000337 · Cited by 45
The use of biologics in pregnant patients with rheumatic disease
Østensen, M. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1305268 · Cited by 41
Early low‐dose rituximab for active thyroid eye disease: An effective and well‐tolerated treatment
Insull, E. A., Sipkova, Z., David, J., Turner, H. E., & Norris, J. H. (2019) · Clinical Endocrinology · doi:10.1111/cen.13970 · Cited by 41
Graalmann, T., Borst, K., Manchanda, H., Vaas, L. A. I., Bruhn, M., Graalmann, L., Köster, M., Verboom, M., Hallensleben, M., Guzmán, C. A., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220435 · Cited by 43
The Neuroimmune Interplay in Joint Pain: The Role of Macrophages
Vasconcelos, D. P., Jabangwe, C., Lamghari, M., & Alves, C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.812962 · Cited by 42
Treating multiple sclerosis with monoclonal antibodies
Buttmann, M., & Rieckmann, P. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.3.433 · Cited by 41
Kraan, T. C. T. M. V. D. P., van Baarsen, L. G. M., Wijbrandts, C. A., Voskuyl, A. E., Rustenburg, F., Baggen, J. M. C., Dijkmans, B. A. C., Tak, P. P., & Verweij, C. L. (2007) · Genes and Immunity · doi:10.1038/sj.gene.6364438 · Cited by 41
The development of targeted therapies in rheumatoid arthritis
Vital, E. M. J., & Emery, P. (2008) · Journal of Autoimmunity · doi:10.1016/j.jaut.2008.04.006 · Cited by 41
Self-citationMultimodal repertoire analysis unveils B cell biology in immune-mediated diseases
Ota, M., Nakano, M., Nagafuchi, Y., Kobayashi, S., Hatano, H., Yoshida, R., Akutsu, Y., Itamiya, T., Ban, N., Tsuchida, Y., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224421 · Cited by 40
Zhou, S., Zhao, G., Chen, R., Li, Y., Huang, J., Kuang, L., Zhang, D., Li, Z., Xu, H., Xiang, W., et al. (2023) · Theranostics · doi:10.7150/thno.90940 · Cited by 43
Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review
Kattamuri, L. P. V., Lal, B. M., Vojjala, N., Jain, M., Sharma, K., Jain, S., & Hadidi, S. A. (2025) · Rheumatology International · doi:10.1007/s00296-024-05772-5 · Cited by 40
Indirect comparison of biological treatments in refractory rheumatoid arthritis
Galisteo, M. G., Rubio, A. V., Rey, E. J. A. D., Márquez-Fernández, E., & Ramos-Báez, J. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01292.x · Cited by 40
Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis
Gensicke, H., Leppert, D., Yaldizli, Ö., Lindberg, R. L. P., Mehling, M., Kappos, L., & Kühle, J. (2011) · CNS Drugs · doi:10.2165/11596920-000000000-00000 · Cited by 42
Mechanisms of tissue damage in arthritis
Blüml, S., Redlich, K., & Smolen, J. S. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0442-8 · Cited by 41
Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort
Slimani, S., Lukas, C., Combe, B. G., & Morel, J. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2010.11.012 · Cited by 40
Wang, Q., Ma, Y., Liu, D., Zhang, L., & Wei, W. (2011) · International Archives of Allergy and Immunology · doi:10.1159/000321185 · Cited by 40
Evaluation of Low-Dose Rituximab Induction Therapy in Living Related Kidney Transplantation
Takagi, T., Ishida, H., Shirakawa, H., Shimizu, T., & Tanabe, K. (2010) · Transplantation · doi:10.1097/tp.0b013e3181dc0999 · Cited by 40
Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease
Suda, T. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23289 · Cited by 41
T-bet expressing B cells – Novel target for autoimmune therapies?
Rubtsov, A. V., Marrack, P., & Rubtsova, K. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.04.011 · Cited by 40
Biosimilars Have Arrived: Rituximab
Greenwald, M., Tesser, J., & Sewell, K. L. (2018) · Arthritis · doi:10.1155/2018/3762864 · Cited by 40
Shen, W., Lee, C., Loh, E., Hsieh, A., Chen, L., & Tam, K. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2111 · Cited by 40
Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
Lorenzo-Vizcaya, A. M., Fasano, S., & Isenberg, D. A. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240874 · Cited by 40
Reddy, V. R., Pepper, R. J., Shah, K., Cambridge, G., Henderson, S. R., Klein, C., Kell, L., Taylor, S. J., Isenberg, D. A., Cragg, M. S., et al. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab827 · Cited by 40
Medical Applications of Leukocyte Surface Molecules—the CD molecules
Zola, H. (2006) · Molecular Medicine · doi:10.2119/2006-00081.zola · Cited by 40
Agarwal, S. K., Glass, R. J., Shadick, N. A., Coblyn, J. S., Anderson, R. J., Maher, N. E., Weinblatt, M. E., & Solomon, D. H. (2008) · PubMed · Cited by 40
X linked agammaglobulinaemia and rheumatoid arthritis
Verbruggen, G., Backer, S. D., Deforce, D. L. D., Demetter, P., Cuvelier, C. A., Veys, E., & Elewaut, D. S. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030049 · Cited by 40
High‐yield production of a human monoclonal IgG by rhizosecretion in hydroponic tobacco cultures
Madeira, L. M., Szeto, T. H., Henquet, M., Raven, N. P. G., Runions, J., Huddleston, J. G., Garrard, I. J., Drake, P. M. W., & K‐C., J. (2015) · Plant Biotechnology Journal · doi:10.1111/pbi.12407 · Cited by 40
Autoimmunity and Autoimmune Disease
Male, D. K., Brostoff, J., Roth, D. B., & Roitt, I. M. (2006) · Elsevier eBooks · doi:10.1016/b0-323-03399-7/50022-2 · Cited by 40
Uncoupling of inflammation and destruction in rheumatoid arthritis: Myth or reality?
van den Berg, W. B., & van Riel, P. L. C. M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20981 · Cited by 39
Antigen-specific immunotherapies for autoimmune disease
Buckner, J. H. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01201-w · Cited by 41
Targeting CD22 as a strategy for treating systemic autoimmune diseases.
Dörner, T., & Goldenberg, D. M. (2007) · PubMed Central · Cited by 39
Cornec, D., Devauchelle‐Pensec, V., Jousse‐Joulin, S., Marhadour, T., Ugo, V., Berthou, C., Douet‐Guilbert, N., & Saraux, A. (2013) · Blood · doi:10.1182/blood-2013-03-491464 · Cited by 39
Rapetti, L., Chavele, K.-M., Evans, C. M., & Ehrenstein, M. R. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204049 · Cited by 39
Wang, S.-P., Iwata, S., Nakayamada, S., Niiro, H., Jabbarzadeh‐Tabrizi, S., Kondo, M., Kubo, S., Yoshikawa, M., & Tanaka, Y. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/keu532 · Cited by 39
The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells
Dai, H., Griffin, N., Bolyard, C. M., Mao, H. C., Zhang, J., Cripe, T. P., Suenaga, T., Arase, H., Nakano, I., Chiocca, E. A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.019 · Cited by 41
Ding, Q., Mohib, K., Kuchroo, V. K., & Rothstein, D. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1602107 · Cited by 39
Jin, W., Luo, Z., & Yang, H. (2020) · Journal of Immunology Research · doi:10.1155/2020/9518137 · Cited by 40
Moon, S., Jhun, J., Ryu, J., Kwon, J. Y., Kim, S. Y., Jung, K., Cho, M., & Min, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245986 · Cited by 39
Kim, H. R., Kim, E. Y., Černý, J., & Moudgil, K. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6634 · Cited by 39
Etanercept in treatment of Felty's syndrome
Ghavami, A., Genevay, S., Fulpius, T., & Gabay, C. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032110 · Cited by 39
Diretrizes para o tratamento da artrite reumatoide
da Mota, L. M. H., Cruz, B. A., Brenol, C., Pereira, I. A., Rezende-Fronza, L. S., Bértolo, M. B., Freitas, M. V. C., da Silva, N. D., Louzada-Junior, P., Giorgio, R. D. N., et al. (2013) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042013000200004 · Cited by 30
Hellmann, M., Jung, N., Owczarczyk, K. M., Hallek, M. J., & RUBBERT, A. (2008) · Lara D. Veeken · doi:10.1093/rheumatology/ken129 · Cited by 39
Anti‐CD20 therapy in systemic lupus erythematosus: A step closer to the clinic
Silverman, G. J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20857 · Cited by 39
Min, H. K., Kim, S. H., Kim, H., & Lee, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213913 · Cited by 38
Cellular interactions in maintaining an inflammatory microenvironment in rheumatoid arthritis
Ganeshalingam, S., Wilson, N. J., Ciciriello, S., Antonipillai, J., & Achuthan, A. A. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.06.008 · Cited by 38
Six refractory lupus patients treated with rituximab: A case series
Gillis, J. Z., Dall’Era, M., Gross, A., Yazdany, J., & Davis, J. C. (2007) · Arthritis Care & Research · doi:10.1002/art.22629 · Cited by 38
Rheumatoid arthritis: Biological therapy other than anti-TNF
Rossi, D., Modena, V., Sciascia, S., & Roccatello, D. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.03.019 · Cited by 38
B cell-targeted therapies in Sjögren's syndrome
Tobón, G. J., Pers, J., Youinou, P., & Saraux, A. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.08.001 · Cited by 38
Castro, L. G., Cogo, N. P., & Volk, L. B. D. S. (2006) · Revista Brasileira de Ciência do Solo · doi:10.1590/s0100-06832006000200014 · Cited by 38
Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis
Segal, B. M., Rhodus, N. L., & Patel, K. S. (2008) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2008.07.025 · Cited by 39
From mechanism to therapies in systemic lupus erythematosus
Paley, M., Strand, V., & Kim, A. H. J. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000369 · Cited by 38
Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients
Toyoda, M., Shin, B., Ge, S., Mirocha, J., Thomas, D., Chu, M., Rodriguez, E., Chao, C., Petrosyan, A., Galera, O. A., et al. (2017) · Journal of Immunology Research · doi:10.1155/2017/5672523 · Cited by 38
Placebo Response in Rheumatoid Arthritis Clinical Trials
Bechman, K., Yates, M., Norton, S., Cope, A. P., & Galloway, J. B. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.190008 · Cited by 38
B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice
Riccio, L. G. C., Jeljeli, M. M., Santulli, P., Chouzenoux, S., Doridot, L., Nicco, C., dos Reis, F. M., Abrão, M. S., Chapron, C., & Batteux, F. (2019) · Human Reproduction · doi:10.1093/humrep/dez071 · Cited by 41
Verhoef, L. M., den Broeder, N., Thurlings, R. M., van der Laan, W. H., van der Weele, W., Kok, M. R., Moens, H. J. B., WOODWORTH, T. G., van den Bemt, B. J. F., van den Hoogen, F. H. J., et al. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30066-9 · Cited by 38
Long term treatment of rheumatoid arthritis with rituximab
Caporali, R. F., Caprioli, M., Bobbio‐Pallavicini, F., Bugatti, S., & Montecucco, C. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.02.008 · Cited by 38
Pathogenic autoantibodies: Emerging insights into tissue injury
Lim, P., & Zouali, M. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.10.023 · Cited by 38
Díaz-Borjón, A. (2009) · Drugs & Aging · doi:10.2165/00002512-200926040-00001 · Cited by 38
González‐Álvaro, I., Domı́nguez-Jiménez, C., Ortiz, A. M., Núñez, V., Roda‐Navarro, P., Fernández‐Ruiz, E., Sancho, D., & Sánchez‐Madrid, F. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1955 · Cited by 38
Parolini, C. (2023) · Marine Drugs · doi:10.3390/md22010017 · Cited by 38
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases
Carter, L. M., Ehrenstein, M. R., & Vital, E. M. J. (2025) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00338-2 · Cited by 37
Rituximab: a review of dermatological applications.
Emer, J. J., & Claire, W. (2009) · PubMed Central · Cited by 37
Merkesdal, S., Kirchhoff, T. D., Wolka, D., Ladinek, G., Kielhorn, A., & Rubbert‐Roth, A. (2009) · The European Journal of Health Economics · doi:10.1007/s10198-009-0205-y · Cited by 37
B-cell therapies in established rheumatoid arthritis
Leandro, M. J., & Becerra-Fernández, E. (2011) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2011.10.005 · Cited by 37
Isvy, A., Meunier, M., Chenevier‐Gobeaux, C., Maury, E., Wipff, J., Job-Deslandre, C., Kahan, A., & Allanore, Y. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2011.12.004 · Cited by 37
Townsend, M. J. (2014) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2014.10.024 · Cited by 37
Shaygannejad, V., Fayyazi, E., Badihian, S., Mirmosayyeb, O., Manouchehri, N., Ashtari, F., & Asgari, N. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09180-9 · Cited by 37
Wu, E., Henkes, Z., McGowan, B., Bell, R. D., Velez, M. J., Livingstone, A. M., Ritchlin, C. T., Schwarz, E. M., & Rahimi, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900473 · Cited by 37
Grandjean, C. L., Garcia, Z., Lemaı̂tre, F., Bréart, B., & Bousso, P. (2021) · Science Advances · doi:10.1126/sciadv.abd6167 · Cited by 37
Singh, J. A., & Cameron, D. R. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.s4-c.1 · Cited by 37
Vital, E. M. J., Kay, J., & Emery, P. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.787064 · Cited by 37
Self-citationSelewski, D. T., Shah, G. V., Mody, R. J., Rajdev, P. A., & Mukherji, S. (2010) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2142 · Cited by 37
Kelly, D. F., Snape, M. D., Perrett, K. P., Clutterbuck, E., Lewis, S., Rohner, G. B., Jones, M., Yu, L., & Pollard, A. J. (2009) · Immunology · doi:10.1111/j.1365-2567.2008.02934.x · Cited by 37
Feldman, R. J., Christen, W. G., & Ahmed, A. R. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10658.x · Cited by 37
Metadata
- Authors
- Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T.
- Affiliations
- University College London (GB)
- University of Wrocław (PL)
- Roche (United Kingdom) (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-17
- Volume
- 350
- Issue
- 25
- Pages
- 2572-2581
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118994799
- Cited by
- 2,623
- References
- 21
- Citations by year
- 2026: 65 · 2025: 69 · 2024: 76 · 2023: 62 · 2022: 61 · 2021: 85 · 2020: 87 · 2019: 85 · 2018: 103 · 2017: 112 · 2016: 96 · 2015: 103 · 2014: 129 · 2013: 133 · 2012: 133
- FWCI
- 109.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, rituximab, B-cell depletion, cyclophosphamide, methotrexate, combination therapy, adverse events, serious infections, immunoglobulin levels, treatment-resistant rheumatoid arthritis, ACR response criteria, EULAR response criteria, maintenance therapy, relapse prevention, long-term follow-up, drug efficacy
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Arthritis, Rheumatoid, B-Lymphocytes, Bacterial Infections, Cyclophosphamide, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Methotrexate, Middle Aged, Antirheumatic Agents, Antigens, CD20, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
